Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMANASDAQ:AVDLNASDAQ:IBBNASDAQ:SANA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$17.88-1.8%$20.47$10.21▼$25.67$4.35B0.433.69 million shs2.39 million shsAVDLAvadel Pharmaceuticals$8.81-0.5%$9.19$6.38▼$17.30$856.14M1.421.23 million shs1.29 million shsIBBiShares Biotechnology ETF$127.63+0.9%$124.06$107.43▼$150.57$5.34B0.731.46 million shs1.77 million shsSANASana Biotechnology$2.83+3.7%$2.23$1.26▼$7.40$615.55M1.853.69 million shs5.81 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics-1.81%+0.17%-10.47%-11.62%+54.81%AVDLAvadel Pharmaceuticals-0.45%-8.23%-3.50%+18.10%-37.61%IBBiShares Biotechnology ETF+0.89%+0.17%+4.78%+0.66%-6.82%SANASana Biotechnology+3.66%-4.71%+31.02%+73.62%-48.26%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMAADMA Biologics4.0815 of 5 stars3.72.00.00.02.72.53.1AVDLAvadel Pharmaceuticals2.5192 of 5 stars3.53.00.00.01.71.70.6IBBiShares Biotechnology ETFN/AN/AN/AN/AN/AN/AN/AN/ASANASana Biotechnology2.5402 of 5 stars3.51.00.00.02.13.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 3.33Buy$27.6754.74% UpsideAVDLAvadel Pharmaceuticals 3.00Buy$18.17106.21% UpsideIBBiShares Biotechnology ETF 2.67Moderate Buy$127.63N/ASANASana Biotechnology 3.00Buy$8.60203.89% UpsideCurrent Analyst Ratings BreakdownLatest AVDL, IBB, SANA, and ADMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025SANASana BiotechnologyJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$5.005/8/2025ADMAADMA BiologicsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$25.00 ➝ $32.005/8/2025AVDLAvadel PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.004/24/2025SANASana BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.004/9/2025AVDLAvadel PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.00(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$426.45M10.01$0.53 per share33.64$1.48 per share12.08AVDLAvadel Pharmaceuticals$169.12M5.04N/AN/A$0.77 per share11.44IBBiShares Biotechnology ETFN/AN/AN/AN/AN/AN/ASANASana BiotechnologyN/AN/AN/AN/A$1.12 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics$197.67M$0.8521.0425.91N/A45.01%47.16%30.51%8/6/2025 (Estimated)AVDLAvadel Pharmaceuticals-$48.83M-$0.27N/A146.83N/A-13.58%-36.07%-16.30%8/6/2025 (Estimated)IBBiShares Biotechnology ETFN/AN/A0.00∞N/AN/AN/AN/AN/ASANASana Biotechnology-$266.76M-$0.88N/AN/AN/AN/A-86.58%-44.49%8/6/2025 (Estimated)Latest AVDL, IBB, SANA, and ADMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025SANASana Biotechnology-$0.22-$0.20+$0.02-$0.21N/AN/A5/7/2025Q1 2025ADMAADMA Biologics$0.16$0.14-$0.02$0.11$116.40 million$114.80 million5/7/2025Q1 2025AVDLAvadel Pharmaceuticals-$0.07-$0.05+$0.02-$0.05$50.57 million$52.51 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/AIBBiShares Biotechnology ETF$0.380.30%N/AN/AN/ASANASana BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.226.583.36AVDLAvadel PharmaceuticalsN/A2.732.33IBBiShares Biotechnology ETFN/AN/AN/ASANASana BiotechnologyN/A3.403.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%AVDLAvadel Pharmaceuticals69.19%IBBiShares Biotechnology ETF62.45%SANASana Biotechnology88.23%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.70%AVDLAvadel Pharmaceuticals5.20%IBBiShares Biotechnology ETFN/ASANASana Biotechnology31.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530238.73 million229.90 millionOptionableAVDLAvadel Pharmaceuticals7096.74 million91.71 millionOptionableIBBiShares Biotechnology ETFN/A42.20 millionN/AOptionableSANASana Biotechnology380225.48 million155.35 millionOptionableAVDL, IBB, SANA, and ADMA HeadlinesRecent News About These CompaniesSana Biotechnology (SANA) Stock Surges on Positive Type 1 Diabetes Treatment ResultsJune 29 at 4:08 AM | insidermonkey.comSana Biotechnology’s SWOT analysis: promising cell therapy stock faces crowded market - Investing.comJune 26, 2025 | investing.comSana Biotechnology (SANA) Receives a Buy from Citizens JMPJune 26, 2025 | theglobeandmail.comSana Biotechnology (NASDAQ:SANA) Earns Market Outperform Rating from JMP SecuritiesJune 26, 2025 | americanbankingnews.comSana Biotechnology (NASDAQ:SANA) Stock Price Down 4.5% - Time to Sell?June 25, 2025 | marketbeat.comSana Biotechnology, Inc. (NASDAQ:SANA) Receives $10.80 Consensus Price Target from BrokeragesJune 25, 2025 | americanbankingnews.comBofA Remains Bullish on Sana Biotechnology (SANA)June 24, 2025 | insidermonkey.comSana Biotechnology (NASDAQ:SANA) Given Market Outperform Rating at JMP SecuritiesJune 24, 2025 | marketbeat.comSana Biotechnology (NASDAQ:SANA) Stock Price Up 17.2% - Should You Buy?June 23, 2025 | marketbeat.comSana Biotechnology stock soars after positive diabetes treatment resultsJune 23, 2025 | investing.comTwo Biotech Stocks Poised For Big Moves On MondayJune 23, 2025 | benzinga.comSana Biotechnology Shares Climb on Positive Diabetes Study ResultsJune 23, 2025 | marketwatch.comSana Biotechnology Reports Promising Six-Month Results from First-in-Human Study on Hypoimmune-Modified Pancreatic Islet Cell Transplant for Type 1 DiabetesJune 23, 2025 | quiverquant.comQSana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without ImmunosuppressionJune 23, 2025 | globenewswire.comSana Biotechnology, Inc. (NASDAQ:SANA) Receives Average Recommendation of "Moderate Buy" from AnalystsJune 22, 2025 | marketbeat.comSana Biotechnology, Inc. (NASDAQ:SANA) Shares Acquired by Clarius Group LLCJune 20, 2025 | marketbeat.comSana Biotechnology (NASDAQ:SANA) Stock Price Up 7.3% - Still a Buy?June 17, 2025 | marketbeat.comSana Biotechnology (NASDAQ:SANA) Trading Down 7.2% - Here's WhyJune 11, 2025 | marketbeat.comSana Biotechnology (NASDAQ:SANA) Shares Up 8.3% - What's Next?June 10, 2025 | marketbeat.comSana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific SessionsJune 9, 2025 | globenewswire.comTwo Sigma Investments LP Grows Holdings in Sana Biotechnology, Inc. (NASDAQ:SANA)June 8, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack Mode3 Penny Stocks Analysts Believe Are Headed HigherBy Chris Markoch | June 4, 2025View 3 Penny Stocks Analysts Believe Are Headed HigherAVDL, IBB, SANA, and ADMA Company DescriptionsADMA Biologics NASDAQ:ADMA$17.88 -0.33 (-1.81%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$17.98 +0.10 (+0.58%) As of 04:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Avadel Pharmaceuticals NASDAQ:AVDL$8.81 -0.04 (-0.45%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$8.90 +0.09 (+1.07%) As of 07/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.iShares Biotechnology ETF NASDAQ:IBB$127.63 +1.12 (+0.89%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$128.21 +0.58 (+0.45%) As of 04:33 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.Sana Biotechnology NASDAQ:SANA$2.83 +0.10 (+3.66%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$2.81 -0.02 (-0.71%) As of 05:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
